Estados financieros detallados de Jasper Therapeutics, Inc. (JSPR): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $0.58, JSPR presenta beneficios negativos (P/E no significativo) y un ROE del -6.19%. La capitalización bursátil es de $9M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | $1.1M |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | -$1.1M |
| I+D | $3.6M | $15.9M | $25.4M | $34.6M | $51.8M | $55.8M | $60.5M |
| Generales y Administrativos | $1.1M | $4.8M | $11.4M | $16.6M | $17.1M | $20.4M | $18.9M |
| Gastos Operativos | $4.7M | $20.7M | $36.8M | $51.2M | $68.9M | $76.2M | $79.5M |
| Beneficio Operativo | -$4.7M | -$20.7M | -$36.8M | -$51.2M | -$68.9M | -$76.2M | -$80.5M |
| EBITDA | 0 | 0 | -$30.3M | -$36.7M | -$63.4M | -$69.9M | -$74.7M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$5.0M | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$5.0M | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M |
| BPA | $0.00 | $-183.08 | $-26.89 | $-10.33 | $-6.18 | $-4.89 | $-3.95 |
| BPA Diluido | $0.00 | $-183.08 | $-26.89 | $-10.33 | $-6.18 | $-4.89 | $-3.95 |
| Acciones en Circulación (Diluidas) | $176000 | $172982 | $1.1M | $3.6M | $10.4M | $14.6M | $19.2M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | -$21000 | 0 |
| Beneficio Operativo | -$19.2M | -$15.8M | -$11.0M | -$9.2M |
| EBITDA | -$18.5M | -$8.8M | -$1.2M | -$2.8M |
| Beneficio Neto | -$18.7M | -$9.1M | -$1.2M | -$2.8M |
| BPA | $-1.13 | $-0.32 | $-0.04 | $-0.10 |
| BPA Diluido | $-1.13 | $-0.32 | $-0.04 | $-0.10 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $27.2M | $19.8M | $84.7M | $38.2M | $86.9M | $71.6M | $28.7M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | $600000 | 0 | 0 | $250000 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $27.2M | $20.7M | $87.8M | $41.7M | $88.9M | $75.8M | $34.6M |
| Inmovilizado Material | 0 | $2.0M | $4.8M | $5.5M | $4.2M | $2.9M | $604000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $27.2M | $23.4M | $93.7M | $48.4M | $94.9M | $79.9M | $35.8M |
| Cuentas por Pagar | $623000 | $1.4M | $3.9M | $1.8M | $4.1M | $4.0M | $6.2M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $2.0M | $4.0M | $8.0M | $7.1M | $12.4M | $15.2M | $13.2M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $6.1M | $58.5M | $24.1M | $12.4M | $16.5M | $18.2M | $31.6M |
| Reservas | -$5.1M | -$36.8M | -$67.5M | -$105.1M | -$169.6M | -$240.9M | -$316.7M |
| Patrimonio Neto | $21.1M | -$35.1M | $69.5M | $36.0M | $78.4M | $61.7M | $4.2M |
| Deuda Total | 0 | $1.6M | $2.9M | $3.7M | $2.8M | $1.8M | $1.2M |
| Deuda Neta | -$27.2M | -$18.2M | -$81.8M | -$34.6M | -$84.1M | -$69.8M | -$27.5M |
| Capital Circulante | $25.2M | $16.7M | $79.8M | $34.7M | $76.6M | $60.6M | $21.4M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $50.9M | $28.7M | $14.1M | $7.3M |
| Activos Totales | $57.5M | $35.8M | $21.2M | $11.8M |
| Pasivos Totales | $45.9M | $31.6M | $17.8M | $10.4M |
| Patrimonio Neto | $11.6M | $4.2M | $3.4M | $1.4M |
| Deuda Total | $1.7M | $1.2M | $757000 | $270000 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$5.0M | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M |
| Amortizaciones | 0 | 0 | $377000 | $1.3M | $1.1M | $1.4M | $1.1M |
| Compensación en Acciones | $6000 | $1.2M | $1.0M | 0 | $5.2M | $6.6M | $6.7M |
| Cambio en Capital Circulante | $1.4M | $1.3M | -$1.3M | -$649000 | $5.1M | $173000 | -$4.9M |
| Flujo de Caja Operativo | -$2.0M | -$18.3M | -$33.7M | -$45.9M | -$52.1M | -$62.6M | -$77.2M |
| Inversiones (CapEx) | 0 | 0 | -$2.4M | -$576000 | -$267000 | -$552000 | -$7000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$2.0M | -$18.3M | -$36.1M | -$46.4M | -$52.3M | -$63.2M | -$77.2M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$17.0M | -$21.9M | -$14.5M | -$6.9M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$17.0M | -$21.9M | -$14.5M | -$6.9M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $1.4M | $1.7M | 0 | $764000 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -535.0% | +3.3% | -23.0% | -71.1% | -10.6% | -6.4% |
| Crecimiento BPA (anual) | | | +85.3% | +61.6% | +40.2% | +20.9% | +19.2% |
| Cambio en Acciones (anual) | | -1.7% | +558.7% | +220.2% | +186.1% | +39.7% | +31.4% |
| Crecimiento FCF (anual) | | -827.7% | -97.7% | -28.6% | -12.7% | -20.7% | -22.2% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-11.19 | $-105.60 | $-31.69 | $-12.73 | $-5.01 | $-4.33 | $-4.03 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $176000 | $172000 | $1.1M | $3.6M | $10.4M | $14.6M | $19.2M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -618.87% |
| Rentabilidad sobre capital invertido | -1305.04% |
| Rentabilidad sobre activos | -269.20% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.19 |
| Ratio corriente | 1.47 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -18.43 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -3.47 | -0.55 | -2.92 | -0.47 | -1.28 | -4.37 | -0.46 |
| P/VC | 0.82 | -0.49 | 1.29 | 0.49 | 1.05 | 5.06 | 8.45 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |